Evidence Pipeline
James Thomas

Trusted evidence.
Informed decisions.
Better health.
The new CRS-Web

Classifer search

Records that have been through the classifier have probabilities assigned to them to indicate how likely they are to have certain properties, like whether they are of interest to a review group, or whether they are likely to be an RCT. Choose the classifier model you are interested in, set the model parameters and click Search to find the records.

<table>
<thead>
<tr>
<th>#</th>
<th>Title</th>
<th>Author</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Cognitive effects of treating obstructive sleep apnea in Alzheimer’s disease: a randomized controlled study</td>
<td>Ancill-Israeli // Palmer BW // Cooke</td>
</tr>
<tr>
<td>2</td>
<td>Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomized, double-blind, placebo-controlled study</td>
<td>Erkinjunti T // Kurz A // Gauthier S // Aban RK</td>
</tr>
<tr>
<td>3</td>
<td>Donepezol improved memory in multiple sclerosis in a randomized clinical trial</td>
<td>Krupp LB // Christodoulou C // Melvill-Hughes J</td>
</tr>
<tr>
<td>4</td>
<td>A randomized, 26-week, double-blind, placebo-controlled trial to evaluate the safety and efficacy of galantamine in the treatment of mild cognitive impairment and Alzheimer’s disease</td>
<td>Aposhian A A // Schmajuk N // Pfeffer R M</td>
</tr>
<tr>
<td>6</td>
<td>A controlled, double-blind, randomized pilot clinical trial of hydroxyxyloril yellow a on cognitive function in patients with vascular dementia</td>
<td>Tian J // Zhao H // Zhou H // Wu H // et al.</td>
</tr>
</tbody>
</table>

The bar chart below shows the classifier scores for this record. Scores are presented in the range 0-1.00 where higher scores mean a higher likelihood that the record is of interest to the group. You can tell a group about this record if it doesn’t already have it in its segment by clicking the bar for that group.

Scores: 99, 79, 57, 29, 23, 10, 15, 15, 11, 11, 11, 10, 9

There is a 99% likelihood that this record is an RCT [Confirm this is not an RCT] [Confirm this is an RCT]
Collection: Direct oral anticoagulants for thromboprophylaxis after orthopedic surgery

Owner: dperezrada@gmail.com

Abstract

Despite current guidelines recommendations about anticoagulant prophylaxis, many studies have shown an high venous thromboembolism (VTE) incidence in patients undergoing total hip and knee arthroplasty. A number of anticoagulants are currently available, but they have some limitations that affect their applicability and consequently their effectiveness. Several new oral anticoagulants (NOACs) have been developed in an attempt to overcome these limitations. Apixaban is a NOAC that selectively inhibits the coagulation factor Xa; it is approved for the prevention of VTE after total hip replacement and total knee replacement surgery. This review examines the results of main trials designed to test efficacy and safety of apixaban in major elective orthopedic surgery.
You can make a difference

Become a Cochrane citizen scientist. Anyone can join our collaborative volunteer effort to help categorise and summarise healthcare evidence so that we can make better healthcare decisions.

Give it a try

Cochrane Crowd
crowd.cochrane.org
Thank you
james.thomas@ucl.ac.uk

Trusted evidence.
Informed decisions.
Better health.